menu
    • menu
    [{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GV20 Therapeutics Presents Preclinical Data on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeting 2024","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"GV20-0251","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GV20 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GV20 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"GV20 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-class Antagonist Antibody Against the Novel Immune Checkpoint IGSF8, in Combination with KEYTRUDA\u00ae (pembrolizumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Collaboration","leadProduct":"GV20-0251","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"GV20 Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GV20 Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"GV20 Therapeutics \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by GV20 Therapeutics

    Menu

    GV20 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GV20 Therapeutics

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            GV20 Therapeutics

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GV20-0251,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-class Antagonist An...

                            Details : Under the agreement, GV20 will evaluate its lead program GV20-0251, a first-in-class antibody targeting the novel immune checkpoint IGSF8, in combination with Merck's anti-PD-1, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors.

                            Brand Name : GV20-0251

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 18, 2024

                            Lead Product(s) : GV20-0251,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GV20 Therapeutics

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            GV20 Therapeutics

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GV20-0251

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GV20 Therapeutics Presents Preclinical Data on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual Meeti...

                            Details : GV20-025 is the first ever AI-designed antibody against an AI-predicated target, which is being evaluated for the treatment of patients with solid tumors.

                            Brand Name : GV20-0251

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 08, 2024

                            Lead Product(s) : GV20-0251

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth